Use of 1,4-dihydro-naphthyridine derivatives in the treatment of tumors - Patents.com

1,4-dihydro-naphthyridine derivatives solve the problem of poor efficacy of traditional anti-tumor drugs by inducing intracellular vacuolation and calcium ion blockade of tumor cells, achieving effective treatment and survival of malignant gliomas.

JP2024543709AActive Publication Date: 2024-11-21NEURODAWN PHARM CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024537031
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-24
Filing Date
2022-11-21
Publication Date
2024-11-21
Estimated Expiration
2042-11-21

AI Technical Summary

Technical Problem

Existing anti-tumor drugs are not effective in treating malignant gliomas (such as glioblastoma), and traditional chemotherapy drugs are difficult to meet clinical needs, and there is a lack of new treatment methods.

Method used

1,4-dihydro-naphthyridine derivatives are used to induce a new death model of tumor cells, intracellular vacuosis, and at the same time inhibit calcium ions inflow, block calcium channels, and thus inhibit tumor cell proliferation.

Benefits of technology

Effectively induce intracellular vacuolization of tumor cells, inhibit tumor growth, significantly prolong patient survival, and have little impact on normal cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543709000001_ABST
    Figure 2024543709000001_ABST
Patent Text Reader

Abstract

The present invention relates to the application of 1,4-dihydro-naphthyridine derivatives in the treatment of tumors.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] cross reference This application claims priority to a Chinese patent application filed with the China Patent Office on December 24, 2021, with application number 202111599362.3, entitled "Use of 1,4-dihydro-naphthyridine derivatives in treating tumors," the entire contents of which are incorporated herein by reference.

[0002] The present invention belongs to the pharmaceutical field and relates to a new use of 1,4-dihydro-naphthyridine derivatives, more specifically, to the application of 1,4-dihydro-naphthyridine derivatives in the manufacture of antitumor drugs. The tumors are solid tumors, including nervous system tumors and non-nervous system tumors. The nervous system tumors include glioblastoma, neuroblastoma, etc. The non-nervous system tumors include liver cancer, colon cancer, gastric cancer, etc. [Background technology]

[0003] Glioblastoma (GBM) is the most common malignant primary intracranial tumor, accounting for approximately 57% of gliomas and 48% of primary central nervous system (CNS) malignancies (Neuro-oncology, 2018.20: p.iv1-iv86). The mortality rate from glioblastoma is very high. In the United States, patients with glioblastoma from 2000 to 2014 had a 1-year survival rate of 41.4% and a 5-year survival rate of only 5.8% (CA: a cancer journal for clinicians, 2020.70(4): p.299-312). The etiology of glioblastoma is still largely unknown, with only ionizing radiation being identified as a possible cause. This brings certain difficulties to the prevention and treatment of glioblastoma.

[0004] According to the malignancy, gliomas are classified into grades I to IV. Among them, grades I and II are less malignant gliomas, and grades III and IV are more malignant gliomas. The treatment of glioblastoma mainly includes surgical resection, radiation therapy, and systemic therapy (chemotherapy, targeted therapy), among which postoperative temozolomide radiation therapy combined with adjuvant chemotherapy has become the standard treatment plan for newly diagnosed glioblastoma. In addition to temozolomide, the current main chemotherapeutic drugs include nitrosoureas, procarbazine, platinums, vinblastines, and camptothecins. However, the antitumor action mechanism of conventional chemotherapeutic drugs cannot meet current clinical needs.

[0005] In eukaryotic cells, macropinocytosis is an important pathway for the internalization of extracellular materials and for the dissolution of molecules. The process of macropinocytosis has a dual effect on tumor cells. In the event of nutritional deficiency, tumor cells can internalize extracellular nutrients through the macropinocytosis pathway, which promotes tumor cell proliferation. However, excessive activation of the macropinocytosis process by drug treatment or abnormal expression of RAS genes can induce a new death mode called methuosis. Methuosis is a new protease-independent cell death mode that is mainly characterized by the cytoplasm being filled with numerous vacuoles derived from macropinocytosomes. This death mode was first discovered in glioblastoma cells (Oncogene, 1999.18(13):p.2281-90). Further research has found that this death mode is caused by clathrin-independent changes in macropinocytosomes, which eventually form numerous vacuoles, leading to cell rupture and death (Journal of medicinal chemistry,2012.55(5):p.1940-56). Current research has found that various molecules, including Ras, Rac1, Arf6, Rab7, etc., are involved in the formation of macropinocytosomes (The American journal of pathology,2014.184(6):p.1630-42). Rac1 may affect the formation of macropinocytosomes by regulating actin assembly. In addition, activation of Rac1 may reduce activated Arf6 via GIT-1, which may further hinder the circulation of macropinocytosomes (Molecular cancer research:MCR,2010.8(10):p.1358-74).In recent years, it has been discovered that several small molecule compounds, including methamphetamine, indolyl chalcone, vaquinol-1, MOMIPP, CX-5011, etc., can induce cellular methotrexate by activating mechanisms such as MKK4, JNK, and Rac1 (Oncotarget 2016,7,55863-55889; BMC cancer 2019,19,77; BBA-Molecular Cell Research 2020,118807).

[0006] 1,4-dihydro-naphthyridine derivatives are compounds that can not only inhibit the activity of acetylcholinesterase, but also block the influx of extracellular calcium ions into cells through calcium channels. By inhibiting the activity of cholinesterase, 1,4-dihydro-naphthyridine derivatives slow down the hydrolysis rate of acetylcholine, improve the acetylcholine level in the synaptic cleft, and treat Alzheimer's disease and vascular dementia (Patent No. CN104203945B, Patent No. CN106632317A). In addition, by suppressing the influx of calcium ions, they can improve the resistance of nerve cells to ischemia, dilate cerebral blood vessels, improve cerebral blood supply, protect neurons, and are also effective in improving the cognitive function of patients with vascular dementia. Summary of the Invention

[0007] 1,4-Dihydro-naphthyridine derivatives are compounds that can not only inhibit acetylcholinesterase activity but also block the influx of extracellular calcium ions into cells through calcium channels, and can be used to treat Alzheimer's disease and vascular dementia. These compounds can exert their antitumor effects by inducing methesis of tumor cells through a new mechanism of action that is independent of cholinesterase inhibition or calcium channel blockade.

[0008] An object of the present invention is to provide a 1,4-dihydro-naphthyridine derivative or a pharma- ceutically acceptable salt thereof, which can treat tumors through a new mechanism and effectively prolong the survival time of patients.

[0009] Specifically, the present invention provides the use of a 1,4-dihydro-naphthyridine derivative of formula I or a pharma- ceutically acceptable salt thereof in the preparation of a medicament for treating a tumor. [ka] where R1 or R2 is hydrogen, halogen, or a C1-C6 alkyl group; R3 is a C1-C6 alkyl group in which any -CH2- may be substituted with one or more -O-; R4 is hydrogen or halogen.

[0010] Specifically, the derivative is selected from the following compounds 1 to 6. Compound 1, designated S1: [ka] Compound 2, designated S2: [ka] Compound 3, designated S3: [ka] Compound 4, designated S4: [ka] Compound 5, designated S5: [ka] Compound 6, designated S6: [ka] .

[0011] The above drugs can induce metastasis of tumor cells to present a vacuolated cell phenotype, and also play a role in inhibiting the proliferation of tumor cells and inhibiting tumor growth, thereby finally achieving the purpose of treating tumors.

[0012] Thus, the present invention provides a novel use of a 1,4-dihydro-naphthyridine derivative or a pharma- ceutically acceptable salt thereof, as well as a pharmaceutical composition thereof, in the manufacture of an antitumor drug.

[0013] The tumor is a solid tumor including nervous system tumors and non-nervous system tumors. The nervous system tumors include glioblastoma, neuroblastoma, etc. The non-nervous system tumors include liver cancer, colon cancer, gastric cancer, etc.

[0014] Specifically, the present invention provides the use of 1,4-dihydro-naphthyridine derivatives in the treatment of solid tumors.

[0015] The present invention provides the use of 1,4-dihydro-naphthyridine derivatives in the treatment of nervous system tumors.

[0016] The present invention provides the use of 1,4-dihydro-naphthyridine derivatives in the treatment of brain tumors.

[0017] The present invention also provides the use of 1,4-dihydro-naphthyridine derivatives in the treatment of glioma.

[0018] The present invention also provides the use of 1,4-dihydro-naphthyridine derivatives in the treatment of glioblastoma.

[0019] The present invention also provides the use of 1,4-dihydro-naphthyridine derivatives in the treatment of liver cancer, colon cancer, and gastric cancer.

[0020] The present invention also provides the use of a combination of a 1,4-dihydro-naphthyridine derivative and temozolomide in the treatment of glioma.

[0021] The present invention also provides the use of a 1,4-dihydro-naphthyridine derivative in combination with radiation therapy in the treatment of glioma.

[0022] Advantages and positive effects of the present invention: The 1,4-dihydro-naphthyridine derivatives provided by the present invention as novel drugs for tumor treatment specifically induce methesis in tumor cells and have little effect on normal cells, which is advantageous for the development of safe and effective drugs for tumor treatment. [Brief description of the drawings]

[0023] [Figure 1] FIG. 1 shows the vacuolation phenotype of T98 cells induced by 1,4-dihydro-naphthyridine derivatives. [Diagram 2] FIG. 2 shows S2-induced vacuolization of various tumor cells. [Diagram 3] FIG. 3 shows that calcium channel inhibitors did not induce vacuolization of tumor cells. [Figure 4] FIG. 4 shows that cholinesterase inhibitors did not induce vacuolization of tumor cells. [Diagram 5] FIG. 5 shows that the combination of a calcium channel blocker and a cholinesterase inhibitor did not induce vacuolization of tumor cells. [Figure 6] FIG. 6 shows the effect of 2 weeks of S2 administration on the growth curve of U87MG glioma in the brain of nude mice. [Figure 7] FIG. 7 shows that S2 treatment for 2 weeks inhibited the growth of U87MG glioma in the brains of nude mice. [Figure 8] FIG. 8 is a graph showing that S2 extended the survival time of nude mice orthotopically implanted with glioma in the brain. [Figure 9]FIG. 9 shows the effect of combined administration of S2+TMZ for 2 weeks on the growth curve of U87MG glioma in the nude mouse brain. [Figure 10] FIG. 10 shows the effect of combined S2+TMZ administration for 2 weeks on glioma growth in the brain. [Figure 11] FIG. 11 is a graph showing that combined administration of S2+TMZ extended survival of mice with U87MG brain intraepithelial carcinoma. [Figure 12] FIG. 12 shows that TMZ failed to inhibit the growth of T98 glioma and failed to reduce the volume and weight of solid tumors. [Figure 13] FIG. 13 shows that S2 inhibited the growth of T98 glioma and reduced the volume and weight of solid tumors. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0024] It should be understood that the following examples are illustrative of the present invention and are not to be construed as limiting the present invention.

[0025] Example 1 Study on the vacuolation-inducing and proliferation-inhibiting effects of 1,4-dihydro-naphthyridine derivatives on glioblastoma cells 1. Materials and Methods 1.1 Cells Human glioma cell line T98G cells were purchased from Nanjing Cobior Biosciences Co., Ltd.

[0026] 1.2 Numbers and structures of 1,4-dihydro-naphthyridine derivatives [Table 1]

[0027] 1.3 Preparation of compound solutions A fixed amount of the test compound was weighed and dissolved in DMSO to prepare a homogenous solution with a final concentration of 100 mM.

[0028] 1.4 Reagents and Consumables [Table 2]

[0029] 1.5 Cell culture and observation of cell phenotype T98G cells were stably passaged twice, and when the cell density reached 85% or more, they were digested with 0.05% trypsin-EDTA for 3 minutes, resuspended in medium, and inoculated into a 12-well plate at a constant density with 1 mL per well. After 24 hours of culture, the compound solutions prepared above were added to each well according to the grouping situation so that the compound concentrations in the culture system were 5 μM, 10 μM, 20 μM, 40 μM, and 60 μM, respectively. An equal volume of DMSO was added as a control well.

[0030] After adding the drug and treating for 6 hours, the cells were observed under a microscope with a 20x objective lens, and five fields of view were randomly selected for each well, photographed, and recorded. If bright vacuoles with clear boundaries appeared in the observed fields and the cells met at least one of the following two conditions: 1) at least one vacuole with a diameter of more than 3 μM, and 2) three or more vacuoles with a diameter of 0.5 to 3 μM, the cells were considered to be methesis-positive cells.

[0031] Vacuolization rate R(%)=CELL 陽性 / (CELL 正常 +CELL 陽性 )×100% Here, CELL 陽性 represents the number of methesis-positive cells, and CELL 正常 represents the number of cells with normal morphology.

[0032] 1.6 Detection of cell proliferation inhibition T98G cells were stably passaged twice, and when the cell density reached 85% or more, they were digested with 0.05% trypsin-EDTA for 3 minutes, resuspended, and seeded into a 96-well plate at a given density. The cells were cultured for 24 hours, and then treated with drugs for 72 hours so that the final concentrations in the culture system were 0.41 μM, 1.23 μM, 3.7 μM, 11.1 μM, 33.3 μM, and 100 μM. TM Cell viability was detected using the CellCounting-Lite 2.0 kit. TM 2.0 According to the kit's instructions, 100 μL / well of reagent was added, shaken for 10 minutes, and the chemiluminescence value (LUM) was read using a multi-function plate reader to calculate the relative survival rate of the cells.

[0033] Relative survival rate of tumor cells V (%) = (LUM-LUM バックグラウンド ) / (LUM 正常対照群 -LUM バックグラウンド群 )×100% However, LUM バックグラウンド is the background reading where detection reagent was added to the complete medium wells. The half maximal inhibitory concentration (IC 50 ) was estimated.

[0034] 2. Experimental Results 2.1 Vacuolation of T98G cells induced by 1,4-dihydro-naphthyridine derivatives S1, S2 (including (+)-S2 and (-)-S2), S3, S4, S5 and S6 were able to induce vacuolation in T98 (Fig. 1 and Table 1). Among these compounds, S1 had the weakest activity of inducing vacuolation, and S2 had the strongest activity of inducing vacuolation.

[0035] [Table 3] In the table, data are expressed as mean ± SD, and "-" indicates that the data was not calculated because the compound precipitated.

[0036] 2.2 Inhibition of T98G cell proliferation by 1,4-dihydro-naphthyridine derivatives Tumor growth inhibitory activity IC shown in Table 2 50 It was found that 1,4-dihydro-naphthyridine derivatives could inhibit the proliferation of neural tumor cells T98G. Among these compounds, S1 had a weaker proliferation inhibitory activity, which was almost consistent with its vacuolation-inducing activity.

[0037] [Table 4]

[0038] Example 2 Study on the inhibitory activity of S2 against tumor cell proliferation in vitro 1. Materials and Methods 1.1 Cells Human glioma cell line U87MG, human glioma cell line T98G and human glioma cell line U251 were purchased from Nanjing Kebai Biotechnology Co., Ltd. Human glioma cell line A172, human neuroblastoma cell line SK-N-SH, human liver cancer cell line HepG2, mouse colon cancer cell line CT26.WT and hamster ovary cell subline CHO-K1 were purchased from Wuhan Pricella Biotechnology Co., Ltd.

[0039] 1.2 Reagents and Consumables [Table 5]

[0040] 1.3 Preparation of dosing solutions The S2 powder was precisely weighed and dissolved in DMSO to prepare a homogeneous solution with a concentration of 100 mM as a mother liquor.

[0041] 1.4 Cell culture and observation of cell phenotype U87MG, T98G, U251, SK-N-SH, A-172, and HepG2 cells were cultured as adherents in MEM + 10% FBS + 1% P / S medium and subcultured at a ratio of 1:3. CT26.WT cells were cultured as adherents in RPMI-1640 + 10% FBS + 1% P / S medium and subcultured at a ratio of 1:3. CHO-K1 cells were cultured as adherents in Ham's F-12K + 10% FBS + 1% P / S medium and subcultured at a ratio of 1:3.

[0042] The cells used above were resuscitated and stably passaged twice. When the cell density reached 85% or more, they were digested with 0.05% trypsin-EDTA for 3 minutes, resuspended in culture medium, and seeded at a constant density in a 6-well plate with 2 mL per well. Cultured for 24 hours. Depending on the grouping situation, 2 μL of the S2 solution prepared above (DMSO final concentration 0.1%) was added to each well so that the S2 concentration in the cell culture system reached 30 μM.

[0043] After adding the drug and treating for 6 hours, the cells were observed under a 20x objective lens, and five fields of view were randomly selected for each well, photographed, and recorded. In the observed fields, bright vacuoles with clear boundaries appeared within the cells, and if at least one of the following two conditions was met: 1) at least one vacuole with a diameter exceeding 3 μM, or 2) three or more vacuoles with a diameter within the range of 0.5 to 3 μM, the cells were recognized as methesis-positive cells (Journal of Medicinal Chemistry 2018 61(12),5424-5434).

[0044] Vacuolization rate R(%)=CELL 陽性 / (CELL 正常 +CELL 陽性 )×100% Here, CELL 陽性 represents the number of methesis-positive cells, and CELL 正常 represents the number of cells with normal morphology.

[0045] 1.5 Cell viability detection Each of the above types of cells was resuscitated and stably passaged twice. When the cell density reached 85% or more, the cells were digested with 0.05% trypsin-EDTA for 3 minutes, resuspended, and seeded into a 96-well plate at a given density and cultured for 24 hours. After 48 hours of drug addition treatment to achieve final concentrations of 0.41μM, 1.23μM, 3.7μM, 11.1μM, 33.3μM, and 100μM in the culture system, the cells were counted by Cell Counting-Lite. TM Cell viability was detected using the Cell Counting-Lite 2.0 kit. TM 2.0 According to the kit's instructions, 100 μL / well of the reagent was added, shaken for 10 minutes, and the chemiluminescence value (LUM) was read using a multi-function plate reader to calculate the relative survival rate of the cells.

[0046] Relative survival rate of tumor cells V (%) = (LUM-LUM バックグラウンド ) / (LUM 正常対照群 -LUM バックグラウンド群 )×100% However, LUM バックグラウンド was the background reading with the detection reagent added to the complete medium wells. The half maximal inhibitory concentration (IC 50 ) was estimated.

[0047] 2. Experimental Results 2.1 S2-induced vacuolation of tumor cells S2 was able to induce vacuolation in neural tumor cells, including human glioma cell lines U87MG, T98G, U251, and A172, and human neuroblastoma cell line SK-N-SH (Fig. 2A-D), and also in non-neural tumor cells, including human liver cancer cell HepG2 and mouse colon cancer cell CT26.WT (Fig. 2A-D). However, S2 did not induce vacuolation in non-tumor cell line hamster ovary cell CHO-K1.

[0048] 2.2 S2 inhibited tumor cell proliferation S2 was able to inhibit the proliferation of neural tumor cells and non-neural tumor lines (IC 50ranged from 4.7 to 14.3 μM), whereas the inhibitory effect on the proliferation of non-tumor cell lines was very weak (IC 50 >100 μM) (see Table 3).

[0049] [Table 6]

[0050] Example 3. Effects of AChE inhibitors and VGCC blockers on T98 cell vacuolation phenotype 1. Materials and Methods 1.1 Cells Human glioma cell line T98G was purchased from COBIOER BIOSCIENCES CO., LTD.

[0051] 1.2 Reagents and Consumables [Table 7]

[0052] 1.3 Preparation of dosing solutions The drugs tested included nifedipine, verapamil, diltiazem, flunarizine and donepezil.

[0053] The above test subject drugs were precisely weighed and dissolved in DMSO to prepare homogeneous solutions with a concentration of 20 mM as mother solutions.

[0054] 1.4 Cell culture and observation of cell phenotype T98G cells were stably passaged twice, and when the cell density reached 85% or more, they were digested with 0.05% trypsin-EDTA for 3 minutes, resuspended in medium, and inoculated into a 12-well plate at a constant density with 1 mL per well. After 24 hours of culture, the compound solutions prepared above were added to each well according to the grouping situation so that the compound concentrations in the culture system were 0.1 μM, 1 μM, 5 μM, and 20 μM, respectively. An equal volume of DMSO was added as a control well.

[0055] After treatment with the drug for 6 hours, the cells were observed under a microscope with a 20x objective lens. If bright vacuoles with clear boundaries appeared within the observed field of view and the cells met at least one of the following two conditions: 1) at least one vacuole with a diameter of more than 3 μM, or 2) three or more vacuoles with a diameter of 0.5 to 3 μM, the cells were considered to be methesis-positive cells.

[0056] 2. Experimental Results 2.1 Calcium channel blockers (VGCCs) were unable to induce vacuolation of tumor cells The calcium channel inhibitors nifedipine, verapamil, diltiazem, and flunarizine (maximum drug concentration 20 μM) were unable to induce a vacuolated cell phenotype in the human glioma cell line T98G (Fig. 3 ).

[0057] 2.2 Cholinesterase (AChE) inhibitors were unable to induce vacuolation of tumor cells. The cholinesterase inhibitor donepezil (maximum drug concentration 20 μM) failed to induce a vacuolated cell phenotype in the human glioma cell line T98G (FIG. 4).

[0058] 2.3 The combined use of calcium channel blockers and cholinesterase inhibitors did not induce vacuolation of tumor cells. The calcium channel blockers nifedipine or verapamil (20 μM) in combination with the cholinesterase inhibitor donepezil (20 μM) failed to induce a vacuolated cell phenotype in the human glioma cell line T98G (FIG. 5).

[0059] Example 4: Efficacy study of S2 against a tumor model in which U87MG-Luc glioblastoma cells were orthotopically transplanted into nude mice 1. Materials and Methods 1.1 Experimental animals ALB / c Nude mice, male, SPF grade, weighing 20–22 g, purchased from LINGCHANG BIOTECHB.

[0060] 1.2 Reagents and Consumables The main reagent information in this experiment is as follows: [Table 8]

[0061] 1.3 Experimental equipment The main equipment information for this experiment is as follows: [Table 9]

[0062] 1.4 Preparation of dosage forms For S2, 5% ethanol + 0.8% solutol + 5% glucose was used as the solvent. Preparation method: take an appropriate amount of S2, add anhydrous ethanol in a specified proportion and dissolve by ultrasonic, add Solutol HS-15 in a specified proportion and mix by ultrasonic (make sure there is no trace phenomenon), slowly add purified water in ultrasonic to dissolve, then add glucose in a specified proportion and dissolve by ultrasonic to obtain a solution, and store the solution at 4℃ away from light.

[0063] 1.5 Experimental Method 1.5.1 Preparation of a tumor model by orthotopically implanting U87MG-Luc glioblastoma cells into nude mice Unseeded U87MG-Luc cells were digested with 0.05% trypsin-EDTA and diluted to 4 × 10 in pre-chilled PBS. 7The nude mice were anesthetized with isoflurane gas, then the anesthetized animals were fixed in a prone position in a stereotaxic apparatus, the scalp of the nude mice was disinfected with iodophor, the scalp of the nude mice was incised sagittally with a scalpel, the incision was cleaned with iodophor, the skull was exposed, and the opening was opened 1.0 mm in front of the bregma and 2.0 mm to the right, and a hole was made using a skull drill. 5 μL of the cell suspension (2 × 10 cells / mL) was then instilled using a 10 μL flat head microsyringe. 5 The needle was inserted at a depth of 3.5 mm, withdrawn at a depth of 0.5 mm, and injected for approximately 10 minutes. After holding the needle in place for 5 minutes, the needle was slowly withdrawn, the incision was sterilized and sutured, and finally 50,000 units of penicillin were injected intramuscularly to prevent infection.

[0064] 1.5.2 Animal Grouping and Dosing In this experiment, the animals were divided into five groups: model group, TMZ group, S2-LD (0.25 mg / kg), S2-MD (0.5 mg / kg), and S2-HD (1 mg / kg). The modeled animals were divided into each group with equal probability in a single-blind manner. From the fifth day after inoculation, the drug was administered intravenously once a day for 15 days. The vehicle was administered intravenously once a day for 15 days to the model group.

[0065] 1.5.3 In vivo imaging of tumor cells in the brain On the 4th, 12th, 18th, and 25th days after inoculation, 200μL of 15mg / mL D-fluorescein potassium salt solution (the solution was sterilized by filtration through a 0.22μM filter) was intraperitoneally injected, and 10 minutes later, IVI chemiluminescence detection (bright field + bioluminescence imaging) was performed using a mouse in vivo imaging system (PE IVIS Lumina XR). Fluorescence intensity analysis was performed using Living Image software to obtain the fluorescence intensity [p / s]. The fluorescence intensity data reflects the size of the tumor tissue in the brain of the experimental animal.

[0066] 1.5.4 Animal survival records The survival status of the experimental animals was detected, and the death dates of the animals were recorded in a timely manner.

[0067] 1.6 Statistical analysis of data Quantitative data are expressed as mean ± standard error. For each pharmacodynamic index, graphs were created using GraphPad Prism (8.0.1) software, and one-way ANOVA or two-way repeat ANOVA was performed to analyze the differences between groups using Fisher's LSD test, and survival analysis was performed using the Kaplan-Meier method. P < 0.05 was defined as significant.

[0068] 2. Experimental Results 2.1 S2 inhibited the growth of U87MG gliomas orthotopically implanted in the brains of nude mice Both S2-MD (0.5 mg / kg, IV) and S2-HD (1 mg / kg, IV) were able to significantly inhibit the growth of U87MG intraepithelial tumors in the brain compared with the vehicle group (Figure 6A and B). After 2 weeks of administration, S2-MD (0.5 mg / kg, IV) and S2-HD (1 mg / kg, IV) showed significant tumor growth inhibition effects compared with the vehicle group. Among them, S2-HD (1 mg / kg, IV) had the strongest tumor inhibition effect (Figure 7A and B).

[0069] 2.2 S2 extends the survival time of nude mice orthotopically transplanted with gliomas in the brain Survival curve analysis was performed using the log-rank test, and the results showed that the survival rate of U87MG brain intraepithelial carcinoma mice was significantly extended in the S2-MD (0.5 mg / kg, IV) and S2-HD (1 mg / kg, IV) groups compared with the vehicle group (Figure 8), and the median survival time and overall survival time were also extended (Table 4).

[0070] [Table 10]

[0071] Example 5: Efficacy study of the combination of S2 and temozolomide (TMZ) on a tumor model in which U87MG-Luc glioblastoma cells were orthotopically transplanted into nude mice 1. Materials and Methods 1.1 Experimental animals The same as in Example 4.

[0072] 1.2 Reagents and consumables The same as in Example 4.

[0073] 1.3 Experimental equipment The same as in Example 4.

[0074] 1.4 Preparation of Dosage Formulations a) S2 Solvent: 5% ethanol + 0.8% solutol + 5% glucose Preparation method: take an appropriate amount of S2, add anhydrous ethanol in a specified proportion and dissolve by ultrasonic, add Solutol HS-15 in a specified proportion and mix by ultrasonic (make sure there is no trace phenomenon), slowly add purified water in ultrasonic to dissolve, then add glucose in a specified proportion and dissolve by ultrasonic to obtain a solution, and store the solution at 4℃ away from light.

[0075] b) TMZ Solvent: 0.9% sodium chloride injection Preparation method: Weigh out an appropriate amount of TMZ, dilute it by adding 0.9% sodium chloride injection in a given proportion, shake until it is uniformly mixed, and store the solution at -20℃.

[0076] 1.5 Experimental Method 1.5.1 Preparation of a tumor model by orthotopically implanting U87MG-Luc glioblastoma cells into nude mice The same as in Example 4.

[0077] 1.5.2 Animal Grouping and Dosing The experiment was divided into four groups: model group, TMZ (3 mg / kg) group, S2 + TMZ combined administration group-LD (TMZ 3 mg / kg and S2 0.25 mg / kg), S2 + TMZ combined administration group-MD (TMZ 3 mg / kg and S2 0.5 mg / kg), and S2 + TMZ combined administration group-HD (TMZ 3 mg / kg and S2 1 mg / kg). The modeled animals were divided into each group in a single-blind manner with equal probability. From the 8th day after inoculation, TMZ was administered intraperitoneally twice on the 8th and 15th days, and S2 was administered intravenously once a day for 15 consecutive days.

[0078] 1.5.3 In vivo imaging of tumor cells in the brain On the 7th, 14th and 21st day after inoculation, 200μL of 15mg / mL D-fluorescein potassium salt solution (the solution was sterilized by filtration through a 0.22μM filter) was intraperitoneally injected, and 10 minutes later, IVI chemiluminescence detection (bright field + bioluminescence imaging) was performed using a mouse in vivo imaging system (PE IVIS Lumina XR). Fluorescence intensity analysis was performed using Living Image software to obtain the fluorescence intensity [p / s]. The fluorescence intensity data reflected the size of the tumor tissue in the brain of the experimental animals.

[0079] 1.5.4 Recording of Animal Survival Periods The survival status of the experimental animals was monitored, and the death dates of the animals were properly recorded.

[0080] 1.6 Data Statistical Analysis Quantitative data are expressed as mean ± standard error. For each pharmacodynamic index, graphs were created using GraphPad Prism (8.0.1) software, and one-way ANOVA or two-way repeat ANOVA was performed to analyze the differences between groups using Fisher's LSD test, and survival analysis was performed using the Kaplan-Meier method. P < 0.05 was defined as significant.

[0081] 2. Experimental Results 2.1 Effect of combined administration of S2 + TMZ on the growth of U87MG glioma in the nude mouse brain TMZ (3 mg / kg, IP) alone and TMZ+S2 (0.25, 0.5, and 1 mg / kg, IV) combined administration were both able to significantly inhibit the growth of U87MG intraepithelial tumors in the brain compared to the vehicle group (Figure 9, A and B). After 2 weeks of administration (on the 21st day), the S2+TMZ combined administration group had a stronger tumor growth inhibitory effect compared to TMZ. In addition, the S2 (0.5 mg / kg)+TMZ combined administration group had a significantly better tumor inhibitory effect than the TMZ group (Figure 10, A and B).

[0082] 2.2 Effect of combined administration of S2 and TMZ on survival of nude mice bearing brain intraepithelial gliomas Survival curve analysis was performed using the log-rank test, and it was found that the TMZ (3 mg / kg, IP) single-administration and TMZ+S2 (0.25, 0.5 and 1 mg / kg, IV) combined administration groups had a significant difference in the survival time of mice compared to the vehicle group. Compared with TMZ single-administration, S2 (0.5 mg / kg)+TMZ combined administration and S2 (1 mg / kg)+TMZ significantly extended the survival rate of mice bearing U87MG intraepithelial brain carcinoma (Figure 11), and also extended the median survival time and overall survival time (Table 5).

[0083] [Table 11]

[0084] Example 6 In vivo pharmacodynamic study of S2 against human glioma T98G in a NOD SCID mouse subcutaneous model 1. Methods and Materials 1.1 Experimental animals NOD SCID, female, 6–8 weeks old, weighing 18–21 g, purchased from Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd.

[0085] 1.2 Test Drug Temozolomide (TMZ) purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., lot number B1828132 S2 purchased from Jiangsu Simovay Medicine Co Ltd under lot number D12-20161101-7

[0086] 1.3 Preparation of dosage forms TMZ (1.5 mg / mL) was prepared by weighing out 18 mg of temozolomide and dissolving it in 12 mL of 1% HPMC. An S2 administration formulation was prepared in the same manner as in Example 4.

[0087] 1.4 Experimental Method 1.4.1 Preparation of a tumor model by subcutaneously implanting T98G glioblastoma cells into nude mice Human glioma T98G cells were cultured in vitro. The culture conditions were EMEM medium supplemented with 10% fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin, and the cells were cultured at 37°C in a 5% CO2 incubator. When the cell number reached the required number, the cells were harvested. T98G tumor cells (PBS:Matrigel = 1:1) 0.2 mL (10 × 10 6 ) was subcutaneously inoculated into the right dorsal region of each mouse. The mean tumor volume was approximately 147 mm 3 When this reached the age, the animals were divided into groups and treatment was started.

[0088] 1.4.2 Animal Grouping and Dosing In the first set of experiments, the modeled animals were divided into two groups, 10 animals each, in a single-blind manner with equal probability: a vehicle group and a TMZ group (15 mg / kg, PO).

[0089] In the second set of experiments, the modeled animals were divided into two groups of 9 animals each in a single-blind manner with equal probability: a vehicle group and an S2 group (3 mg / kg, IV).

[0090] 1.4.3 Tumor size measurement Tumor diameters were measured twice weekly with a caliper and tumors were weighed and photographed at the end of the experiment.

[0091] 1.5 Data Statistics Tumor volume calculation formula: V = 0.5a × b 2 (where a and b represent the long and short diameters of the tumor, respectively) The antitumor effect was evaluated by TGI (%) or relative tumor proliferation rate T / C (%). The antitumor effect TGI (%) was calculated according to the following formula: TGI%=[1-(mean tumor volume at the end of treatment in a treatment group-mean tumor volume at the start of treatment in the treatment group) / (mean tumor volume at the end of treatment in the vehicle control group-mean tumor volume at the start of treatment in the vehicle control group)]×100 The relative tumor proliferation rate T / C (%) was calculated using the following formula: T / C%=TRTV / CRTV×100 (where TRTV represents the RTV of the treatment group, and CRTV represents the RTV of the negative control group) Relative tumor volume (RTV) was calculated from the tumor measurement results using the following formula: RTV is calculated as follows: RTV=V t / V0 (where V0 is the mean tumor volume measured at the start of treatment (i.e., d0), and V t is the mean tumor volume at a given measurement, and T RTV and C. RTV are data taken on the same day).

[0092] Statistical analysis was performed based on the mean and standard error of the mean (SEM) of tumor volume in each group at the end of the experiment. Comparison between two groups was analyzed using T-test. All data analysis was performed with GraphPad Prism (8.0.1). Differences were considered significant when P<0.05.

[0093] 2. Experimental Results 2.1 Effect of TMZ on T98 tumor growth and tumor weight at the experimental endpoint Compared to the vehicle group, the TMZ 15 mg / kg group showed no inhibitory effect on tumor volume growth (FIG. 12, A-C). When the tumors were harvested and weighed at the end of the experiment, there was no significant difference in tumor weight between the TMZ 15 mg / kg group and the control group (FIG. 12, D). This result was consistent with the inhibition of tumor volume described above.

[0094] 2.2 Effect of S2 on T98 tumor growth and tumor weight at experimental endpoints Compared to the vehicle group, the tumor volume growth was significantly inhibited in the S2 3 mg / kg group (FIG. 13A-C). When the tumors were harvested and weighed at the end of the experiment, the tumor weight was significantly lower in the S2 3 mg / kg group than in the control group (FIG. 13D). This result was consistent with the inhibition of tumor volume described above.

Claims

1. Use of a 1,4-dihydro-naphthyridine derivative represented by the following formula I or a pharma- ceutically acceptable salt thereof in the preparation of a medicament for treating a tumor. [Formula 1] (Here, R 1 Or R 2 is hydrogen, halogen, or a C1-C6 alkyl group; R 3 is any of the -CH 2 - is a C1-C6 alkyl group optionally substituted with one or more -O-, R 4 is hydrogen or halogen.)

2. Use of any one of 1,4-dihydro-naphthyridine derivatives selected from the following compounds 1 to 6 or a pharma- ceutically acceptable salt thereof in the preparation of a medicament for treating a tumor. Compound 1 represented by S1: [Case 2] Compound 2 represented by S2: [C3] Compound 3 represented by S3: [C4] Compound 4 represented by S4: [C5] Compound 5 represented by S5: [C6] Compound 6 represented by S6: [C7] .

3. The use according to claim 2, characterized in that it is the use of said 1,4-dihydro-naphthyridine derivatives in the treatment of solid tumors.

4. The use according to claim 2, characterized in that it is the use of said 1,4-dihydro-naphthyridine derivatives in the treatment of nervous system tumors.

5. The use according to claim 2, characterized in that the 1,4-dihydro-naphthyridine derivatives are used in the treatment of brain tumors.

6. The use according to claim 2, characterized in that it is the use of said 1,4-dihydro-naphthyridine derivatives in the treatment of glioma.

7. The use according to claim 2, characterized in that it is the use of said 1,4-dihydro-naphthyridine derivatives in the treatment of glioblastoma.

8. The use according to claim 2, characterized in that the 1,4-dihydro-naphthyridine derivatives are used in the treatment of liver cancer, colon cancer and gastric cancer.

9. The use according to claim 2, characterized in that the 1,4-dihydro-naphthyridine derivative is combined with temozolomide for treating glioma.

10. The use according to claim 2, characterized in that the 1,4-dihydro-naphthyridine derivatives are combined with radiotherapy to treat gliomas.

Citation Information

Patent Citations

  • Set of derivatives of 5-amino-1,4-dihydro(1,8) naphthyridine 3-carboxylic acid for use in preparation of e.g. Alzheimer and Parkinson disease medicines

    ES2277741A1

  • 1,4-Dihydro-naphthyridine derivatives and their pharmaceutical compositions and uses

    JP2015500250A